Advertisement

Paraneoplastic Dermatomyositis

Published:February 24, 2022DOI:https://doi.org/10.1016/j.amjmed.2022.01.016
      A Hispanic man in his 50s—recently diagnosed with acral lentiginous melanoma—presented for evaluation of a tender, photodistributed rash that was first appreciated approximately 10 weeks prior. Review of systems was notable for difficulty lifting objects above his head.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Qiang JK
        • Kim WB
        • Baibergenova A
        • Alhusayen R.
        Risk of malignancy in dermatomyositis and polymyositis.
        J Cutan Med Surg. 2017; 21: 131-136
        • Fiorentino DF
        • Chung LS
        • Christopher-Stine L
        • et al.
        Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.
        Arthritis Rheum. 2013; 65: 2954-2962
        • Hill CL
        • Zhang Y
        • Sigurgeirsson B
        • et al .
        Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study.
        Lancet. 2001; 357: 96-100
        • Schiller M
        • Böhm M
        • Hensen P
        • Riemann H
        • Luger TA
        • Nashan D.
        Dermatomyositis associated with malignant melanoma—A marker of poor prognosis?.
        J Am Acad Dermatol. 2006; 54: 221-226